Key Words

Though cervical cancer incidence and prevalence have decreased in the United States, the disease remains a very important cause of morbidity and mortality worldwide. Current therapy for early-stage disease is surgical with adjuvant therapy being administered accord-ing to histopathologic findings. Pelvic radiation with concomitant platinum-based chemotherapy is used to treat locally advanced dis-ease, whereas metastatic and recurrent lesions continue to be dif-ficult to effectively treat and cure. Clinical trials in this latter scenario have suggested that clinical benefit may be associated with biologic therapies. This article focuses on the use of targeted therapies in cer-vical cancer, specifically evaluating antiangiogenesis and endothelial growth factor receptor–related treatments. (JNCCN 2010;8:1417– 1423) Epidemiology In the United States, 11,270 new cases of cervical can-cer and 4070 associated deaths occurred in 2009.1 These numbers represent a significant decline in incidence and prevalence that is attributed to excellent screen-From the aDivision of Gynecologic Oncology, Department o